Study for the effects of Etidronate on miro-metastatic lesions of neuroblastoma in bones

2001 Fiscal Year Final Research Report Summary

• Project/Area Number: 11671766
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Pediatric surgery
• Research Institution: Chiba University
• Principal Investigator: TANABE Masahiro CHIBA UNIVERSITY HOSPITAL, Graduate and Continuing Medical Education Center, Professor, 医学部・附属病院, 教授 (10207160)
• Co-Investigator(Kenkyū-buntansha): KOUCHI Katsunori Chiba University, University Hospital, Pediatric Surgery, Assistant, 医学部・附属病院, 助手 (40312938) ; MATSUNAGA Tadashi Chiba University, University Hospital, Pediatric Surgery, Lecture, 医学部・附属病院, 講師 (80302561) ; YOSHIDA Hideo Chiba University School of Medicine, Pediatric Surgery, Assistant Professor, 大学院, 研究院・助教授 (60210712)
• Project Period (FY): 1999 – 2001
• Keywords: neuroblastoma / Etidronate / bone metastasis / murine neuroblastoma

Research Abstract

To elucidate the effects of Etidronate, osteoclast activity inhibitor, on bone metastasis formation of neuroblastoma bone metastases were analyzed histologically in a hematogeneous metastasis model of murine neuroblastoma. The bone metastasis was significantly suppressed in mice treated with Etidronate before bone metastasis formation in comparison with those after bone metastasis formation. However, it was not shown that Etidronate reduced the number of osteoclast and caused to inhibit bone metastasis formation of neuroblastoma. It is likely that Etidronate is useful to prevent new formation and recurrence of bone metastasis of neuroblastoma rather than to treat established bone metastasis. To improve the results of treatment of advanced neuroblastoma with bone metastasis Etidronate seems to be used to prevent the recurrence of bone metastasis after complete remission of disease.